NEW YORK (GenomeWeb) – CollabRx said this week that Singapore-based private oncology firm OncoSolutions Cancer Center has signed a multi-year agreement to use CollabRx's Genetic Variant Annotation (GVA) service to analyze tumor genetic data.
The OncoSolutions deal is CollabRx's "first such commercial relationship with a private oncology company," Thomas Mika, chairman, president and CEO of CollabRx, noted in a statement. He added the agreement also expands the company's presence in Asia.
Financial and other terms of the agreement were not disclosed.
CollabRx launched GVA last year to provide variant interpretation services to the clinical laboratory research market including hospital labs, research institutions and academic medical centers. The service pairs the results of genetic sequencing tests with clinically actionable information such as the impact of specific genetic profiles and associated therapeutic strategies – drugs and clinical trials – that can be used to inform patient treatment.